October 20, 2021
Dupixent® (dupilumab) can now be used to treat asthma in a wider age group, as the U.S. FDA has expanded its asthma indication to include children ages 6-11 years. It was previously approved to treat asthma only in adults and in children at least 12 years old.
- Under the indication, Dupixent is approved as an add-on maintenance therapy for moderate-to- severe asthma with an eosinophilic phenotype or oral corticosteroid-dependent
- Recommended dosing for children 6-11 years old is based on weight and whether the patient also has moderate-to-severe atopic
- Dupixent first received FDA approval in 2017 and is also indicated to treat moderate-to-severe atopic dermatitis (ages 6 years and up) and chronic rhinosinusitis with nasal polyposis (adults).